The pharmaceutical company Eczacibasi Group plans to invest over EUR 250m in its operations, create more than 1,500 new jobs, and reach an annual turnover of over EUR 150m in 2022 when it celebrates its 80th anniversary, according to Atalay Gumrah, CEO of Eczacibasi. “We’ll primarily develop our R&D activities in nuclear medicine and invest...
Latest News:
The arms issue
What matters on Thursday, February 3
Everyone plays a waiting game
What matters on Wednesday, February 1
Six-party opposition roundtable announces the Common Policies Text
Expensive export and cheap import records were broken
What matters on Tuesday, January 31
Economic confidence on the rise
What matters on Monday, January 30
What matters on Friday, January 27
Macroprudential measures can’t replace monetary policy: TUSIAD
Digital transformation of Chinese commercial banks: OPINION
The sustainable advantages of purchasing second-hand products
It’ll be enough to manage until the election!
What matters on Wednesday, January 25
Startups receive USD 1.6bn funding in 2022
Domestic tourism expenditures skyrocket
Consumer confidence hits 16-month high
What matters on Monday, January 23
Home
Eczacibasi Group